Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the [CAMN107A2109] study

Phase 4

Novartis Pharmaceuticals

Imatinib Mesylate